1Schmieder RE,Martus P, Klingbeil A.Reversal of left ventricular hypertrophy in essential hypertension.A meta-analysis of randomized double-blind studies[J].JAMA, 1996,275(19): 1507-1513.
2Gottdiener JS,Reda DJ,et al.Left atrial size in hypertensive men: influence of obesity, race and age.Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents[J].J Am Coll Cardiol, 1997,29(3):651-658.
1[1]Singh JP,Larson MG,Tsuji H,et al.Reduced heart rate variability and new-onset hypertension:insights into pathogenesis of hypertension:the Framingham heart study.Hypertension,1998,32:293-294.
2[8]Ylitalo A,Airaksinen KE,Sellin L,et al.Effects of combination antihypertensive therapy on baroreflex sensitivity and HRV in systemic hypertension.Am J Cardiol,1999,83:885-889.
1Smith DH. Comparison of angiotensinⅡ type 1 receptor antagonists in the treatment of essential hypertension [ J ]. Drugs, 2008, 68 (9) : 1207 -1225.
2Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension [ J ]. Drugs, 2008, 68 ( 9 ) : 1239 - 1272.
3Sheu JJ, Chang LT, Chiang CH, et al. Impact of diabetes on car-diomyocyte apoptosis and connexin43 gap junction integrity : role of pharmacological modulation [ J ]. Int Heart, 2007, 48 ( 2 ) : 233 - 245.
4Owada A, Suda S, Hata T, et al. The effects of bisoprolol, a se- lective betal -blocker, on glucose metabolism by long- term ad- ministration in essential hypertension [ J ]. Clin Exp Hypertens, 2001, 23(4) : 305 -316.
